I psoriasisforsøg 2 sås der også en signifikant forbedring i Hospital Anxiety and Depression Scale (HADS) og
In Psoriasis Study 2, the Hospital Anxiety and Depression Scale (HADS) and Work Limitations Questionnaire (WLQ) were also significantly improved in each ustekinumab treatment group compared with placebo.